Physician profile
Luis D Usuga
NPI 1336214048
$29,124.12
in general payments reported to CMS, 2019-2025
38 companies · $4,721 in 2025
The $4,721 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $21K · 2021: $806 · 2022: $390 · 2023: $571 · 2024: $354 · 2025: $4,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,049 · Education: $1,693 · Food and Beverage: $1,304 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,048.94 |
| Education | $1,693.35 |
| Food and Beverage | $1,304.06 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21,088.87 | 2019-2020 | |
| Intuitive Surgical, INC. | $2,709.01 | 2025 | |
| Coloplast Corp | $1,541.39 | 2019-2025 | |
| Mimedx Group, INC. | $615.71 | 2024-2025 | |
| Abbvie INC. | $533.87 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $530.95 | 2019-2025 | Slynd |
| Millicent US INC | $261.64 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Vivus LLC | $203.55 | 2019-2024 | Qsymia |
| Novo Nordisk INC | $203.34 | 2019-2025 | Wegovy, Saxenda |
| Mayne Pharma Commercial LLC | $190.55 | 2021-2025 | |
| Pfizer INC. | $129.84 | 2023-2024 | |
| Shield Therapeutics INC | $114.46 | 2024 | |
| Therapeuticsmd, INC. | $90.40 | 2019-2022 | |
| Teleflex LLC | $89.96 | 2019 | |
| Currax Pharmaceuticals LLC | $79.25 | 2020-2024 | Contrave, Onzetra Xsail |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $77.43 | 2019-2023 | Balcoltra |
| Mission Pharmacal Company | $72.67 | 2019-2021 | |
| Astellas Pharma US INC | $62.45 | 2023-2024 | Veozah |
| Applied Medical Resources Corporation | $51.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.53 | 2021-2022 | |
| Evofem Biosciences, INC. | $40.09 | 2021 | |
| Hologic Sales and Service, LLC | $36.78 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $32.15 | 2019 | |
| Organon LLC | $29.82 | 2024 | |
| Minerva Surgical, INC | $29.46 | 2021 | |
| Daiichi Sankyo INC. | $27.83 | 2023 | Injectafer |
| Scynexis, INC. | $26.62 | 2022 | |
| Eisai INC. | $26.40 | 2019 | |
| Merck Sharp & Dohme LLC | $25.92 | 2019 | |
| Axonics, INC. | $24.33 | 2023 | Bulkamid |
| Sumitomo Pharma America, INC. | $23.45 | 2024 | Myfembree |
| Davol INC. | $21.89 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $21.64 | 2023 | Vivjoa |
| Myovant Sciences INC. | $18.16 | 2022 | |
| Kesin Pharma Corporation | $14.74 | 2023 | Likmez |
| Lupin INC. | $13.14 | 2019 | |
| Dysis Medical, INC. | $12.98 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Usuga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.